Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rintatolimod + pembrolizumab
- Development stage
- Unknown
- Lead developer
- AIM ImmunoTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Rintatolimod + pembrolizumab is an investigational combination immunotherapy regimen being evaluated for the treatment of refractory, metastatic, microsatellite stable (MSS) colorectal cancer. Rintatolimod (Ampligen) is a synthetic double-stranded RNA (dsRNA) molecule that acts as a selective Toll-like receptor 3 (TLR3) agonist. It functions as a chemokine-modulating agent, designed to 'inflame' the tumor microenvironment by inducing the production of specific chemokines that attract cytotoxic T lymphocytes (CTLs) and increasing the expression of PD-L1. Pembrolizumab (Keytruda) is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 to restore anti-tumor immune responses. The combination is being studied by Roswell Park Comprehensive Cancer Center to overcome the resistance of MSS colorectal tumors to standard checkpoint inhibitor monotherapy by converting 'cold' tumors into 'hot' tumors.
- Brand names
- Ampligen + Keytruda
- Other names
- rintatolimod and pembrolizumab combination
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on rintatolimod + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rintatolimod + pembrolizumab.